查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790242

美國Tremfya 市場規模、佔有率和趨勢分析報告：按應用、分銷管道和細分市場預測，2025 年至 2033 年

U.S. Tremfya Market Size, Share & Trends Analysis Report By Application (Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis ), By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國Tremfya 市場規模與趨勢

預計 2024 年美國Tremfya 市場規模為 30 億美元，到 2033 年將達到 48.9 億美元，2025 年至 2033 年的複合年成長率為 5.32%。

在美國，慢性尋常性乾癬和乾癬性關節炎的盛行率不斷上升，這導致對先進生技藥品治療的需求不斷成長。隨著這些自體免疫疾病的日益普遍，人們越來越重視能夠持久控制疾病並改善患者預後的治療方法。 IL-23 抑制劑 Tremfya（guselkumab）已證明在治療中度至重度乾癬病例方面具有可靠的療效。

Tremfya 能夠持久緩解症狀，且安全性良好，因此有望被更廣泛地採用。包括皮膚科醫生和風濕症醫師在內的美國醫療保健專業人士擴大將 Tremfya 納入治療方法。這一趨勢反映了人們正轉向與長期管理目標相符的精準標靶生技藥品。

Tremfya 在美國的商業性成長得益於楊森製藥有效的行銷和穩健的競爭策略。該療法已在生技藥品市場確立了顯著地位，其療效優於多種成熟療法，包括 TNF 抑制劑和 IL-17 抑制劑。臨床對比結果突顯了其快速的皮膚清除和長期療效。例如，2024 年 10 月，強生公司的 SPECTREM 研究表明，Tremfya 有效清除了頭皮、臉部、手腳和生殖器等難治性牛皮癬區域，清除率高達 80%。大多數患者在 48 週內保持皮膚清潔或接近清潔。該療法還減輕了瘙癢和疼痛等症狀，顯著改善了患者的生活品質。

Tremfya 在美國市場的未來成長得益於其持續的臨床開發和生命週期管理策略。目前的臨床試驗正在評估其在克隆氏症和化膿性汗腺炎適應症的應用，並有望擴大其治療範圍。製造商也正在進行真實世界證據研究，以驗證其在不同病患小組中的有效性。人們對個人化醫療和生物標記驅動治療的興趣日益濃厚，這推動了對 IL-23 抑制劑的需求。與專科藥房的合作以及高效的分銷系統正在改善重點地區的藥物可及性。持續投資於醫師培訓和病患支援計劃，增強了品牌的參與度。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國Tremfya 市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章美國Tremfya 市場：應用業務分析

  • 2024 年和 2033 年應用市場佔有率
  • 應用程式細分儀表板
  • 市場規模、預測與趨勢分析（按應用，2021-2033 年）
  • 斑塊型乾癬
  • 乾癬性關節炎（PsA）
  • 其他

第5章美國Tremfya 市場：通路業務分析

  • 2024年及2033年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第6章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Johnson & Johnson Services, Inc.
Product Code: GVR-4-68040-651-2

U.S. Tremfya Market Size & Trends:

The U.S. Tremfya market size was estimated at USD 3.00 billion in 2024 and is projected to reach USD 4.89 billion by 2033, growing at a CAGR of 5.32% from 2025 to 2033. The rising incidence of chronic plaque psoriasis and psoriatic arthritis in the U.S. is contributing to increased demand for advanced biologic treatments. As these autoimmune disorders become more widespread, there is a growing emphasis on therapies that offer lasting disease control and improved patient outcomes. Tremfya (guselkumab), an IL-23 inhibitor, has demonstrated reliable effectiveness in managing moderate-to-severe forms of these conditions.

Its ability to provide sustained symptom relief, combined with a well-tolerated safety profile, has supported its broader adoption. U.S. healthcare professionals, including dermatologists and rheumatologists, are increasingly incorporating Tremfya into treatment regimens. This trend reflects a shift toward precision-targeted biologics that align with long-term management goals.

Tremfya's commercial growth in the U.S. is strongly supported by Janssen Pharmaceuticals' effective marketing efforts and robust competitive strategy. The therapy has carved out a distinct position in the biologics market by demonstrating higher efficacy than several established treatments, such as TNF and IL-17 inhibitors. Clinical comparisons have highlighted its ability to deliver faster skin clearance and maintain results over time. For instance, in October 2024, Johnson & Johnson's SPECTREM study showed Tremfya effectively cleared difficult psoriasis areas like the scalp, face, hands, feet, and genitals, with clearance rates up to 80%. Most patients maintained clear or almost clear skin through week 48. The treatment also significantly improved patients' quality of life by reducing symptoms like itch and pain.

The future growth of the Tremfya market in the U.S. is supported by ongoing clinical development and lifecycle management strategies. Current trials are assessing its use in additional indications such as Crohn's disease and hidradenitis suppurativa, potentially expanding its treatment range. The manufacturer is also conducting real-world evidence research to confirm its effectiveness across varied patient groups. Rising interest in personalized medicine and biomarker-focused treatments is boosting demand for IL-23 inhibitors. Collaborations with specialty pharmacies and efficient distribution systems improve access in key regions. Continued investment in physician training and patient support initiatives strengthens brand engagement.

U.S. Tremfya Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Tremfya market report based on application and distribution channel:

  • Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Plaque Psoriasis
  • Psoriatic Arthritis (PsA)
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Tremfya Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Tremfya Market: Application Business Analysis

  • 4.1. Application Market Share, 2024 & 2033
  • 4.2. Application Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Billion)
  • 4.4. Plaque Psoriasis
    • 4.4.1. Plaque Psoriasis Market, 2021 - 2033 (USD Billion)
  • 4.5. Psoriatic Arthritis (PsA)
    • 4.5.1. Psoriatic Arthritis (PsA) Market, 2021 - 2033 (USD Billion)
  • 4.6. Others
    • 4.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. U.S. Tremfya Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
  • 5.6. Online Pharmacies
    • 5.6.1. Online Pharmacies Market, 2021 - 2033 (USD Billion)

Chapter 6. Competitive Landscape

  • 6.1. Participant Overview
  • 6.2. Company Market Position Analysis
  • 6.3. Company Categorization
  • 6.4. Strategy Mapping
  • 6.5. Company Profiles/Listing
    • 6.5.1. Johnson & Johnson Services, Inc.
      • 6.5.1.1. Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Application Benchmarking
      • 6.5.1.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. Tremfya market, by application, 2021 - 2033 (USD Billion)
  • Table 4.U.S. Tremfya market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 U.S. Tremfya market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Billion)
  • Fig. 10 Competitive landscape
  • Fig. 11 U.S. Tremfya market dynamics
  • Fig. 12 U.S. Tremfya market: Porter's five forces analysis
  • Fig. 13 U.S. Tremfya market: PESTLE analysis
  • Fig. 14 Application market, 2021 - 2033 (USD Billion)
  • Fig. 15 Plaque psoriasis market, 2021 - 2033 (USD Billion)
  • Fig. 16 Psoriatic Arthritis (PsA) market, 2021 - 2033 (USD Billion)
  • Fig. 17 Others market, 2021 - 2033 (USD Billion)
  • Fig. 18 Distribution Channel market, 2021 - 2033 (USD Billion)
  • Fig. 19 Hospital pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 20 Retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 21 Online pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 22 U.S. Tremfya market revenue, by region
  • Fig. 23 Country marketplace: Key takeaways
  • Fig. 24 U.S. country dynamics
  • Fig. 25 U.S. Tremfya market, 2021 - 2033 (USD Billion)
  • Fig. 26 Company categorization
  • Fig. 27 Company market position analysis
  • Fig. 28 Strategic framework